drugset / Trial / NCT05112952
A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of a single oral dose of lazertinib in participants with impaired hepatic function when compared with healthy participants with normal hepatic function, under fed conditions.
Timeline
- Start
- 2021-11-30
- Primary completion
- 2022-07-11
- Completion
- 2022-07-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lazertinib | Small molecule | — | Oral |
Indications
No indication recorded.